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Abstract
Modulation and Long-term Release of Cardiac Fibroblast Secretome to Enhance Cardiac Cell
Survival under Hypoxia
By
Jin Zhai
Master of Science in Biomedical Engineering
Washington University in St. Louis, 2021
Professor Jianjun Guan
The irreversible damage to the heart caused by myocardial infarction (MI) leads to over one million
deaths in the United States every year. There are several approaches to treat MI, such as
angioplasty, redirected blood flow, and electrical medical devices, but they cannot promote new
cardiac tissue generation, thus leading to potential high risk of re-surgeries. To overcome this
limitation, stem cell therapy is regarded as a promising method. However, the implantation of stem
cells has ethical and safe concern and the efficiency is limited due to low cell engraftment.
Moreover, the effect of stem cell is predominantly attributed to paracrine effect. Therefore, the
delivery of stem cell secretome is expected to be a prominent approach, since it has potential to
achieve similar effect without causing safety and ethical problems with cell implantation. Among
different cells, cardiac fibroblast (CF) is the largest cell population in the heart, and its secretome
has been shown to protect cardiomyocytes under hypoxia. Thus, the objective of this work is to
deliver CF secretome to the heart after MI. In the first part of this thesis, CF secretome was
optimized in vitro by adjusting environmental oxygen condition and substrate stiffness. We found
that the secretome collected under hypoxic condition (1% O2) and soft substrate (6 kPa) can most
effectively boost the survival of endothelial cells and cardiomyocytes under hypoxia. In the second

viii
part, we developed platelet-membrane coated nanoparticles as a delivery vehicle for CF secretome.
The nanoparticles had the capability of sustainedly releasing various growth factors such as PDGF,
VEGF and bFGF. This secretome delivery system has potential to promote cardiac repair after MI.
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Chapter 1 Introduction
1.1 Myocardial infarction
Myocardial infarction (MI) is the one of main causes of death worldwide. Over one
million deaths due to MI are reported in the United State every year [1]. MI causes irreversible
damage to the heart because of decreasing blood flow and lack of oxygen supply [2]. Currently,
there are several kinds of treatment for MI. Patients can directly take drugs to break up blood clot
or dissolve arterial blockage, such as aspirin and tissue plasminogen activator [2]. Also, some
drugs can be injected in the blood to treat. Moreover, the angioplasty can be performed to open
narrowed blood vessel and let blood flow easily [3]. To redirect blood flow around the blocked
blood vessels, the coronary bypass surgery may be performed [4]. Furthermore, some electronic
medical devices, such as pacemakers, can be implanted in the infarcted heart to keep regular beat
[2]

. For patients with end-stage heart failure, a heart transplantation may be required [2].
After MI, the loss of cardiomyocytes and formation of scar tissues are irreversible,

leading to decreased cardiac function [5]. Thus, it is important to replace the injured cells.
However, the existing surgical treatments are unable to promote the generation of new cardiac
tissue. The application of stem cells can be a promising therapeutic option [6].
1.2 Stem cell therapy to treat MI
The use of stem cells to treat MI is expected by their two conspicuous capacities of selfrenewal and differentiation into tissues [7]. In order to achieve the goal of regenerating the
damaged tissues, the stem cell should be able to differentiate into cardiac lineages, such as
myocytes and vascular endothelial cells [6]. The primary types of stem cells used in treatments for
myocardial infarction are embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs),
bone marrow mononuclear cells (BMMNCs), and mesenchymal stem cells (MSCs) [6]. Among
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these stem cells, both ESCs and iPSCs are pluripotent and able to differentiate into all cell types,
but ESCs may lead to ethical and safety concern, and iPSCs have the tumorigenic possibility [8,9].
BMMNCs has been shown to enhance left ventricular function, but they can differentiate into
heterogeneous cell types which may not be advantaged for heart repair [6]. Although MSCs
perform the immune-privileged ability , its cell retention, engraftment, and survival rate still is
low [6].
Based on the above disadvantages of stem cell therapy, stem cell secretome has emerged
as a promising therapeutic option. It has been shown that the key element of stem cell therapy
should be attributed to its paracrine mechanism to promote regeneration [10].
1.3 Cell secretome
Stem cells can affect the surrounding cells by secreting soluble growth factors, cytokines,
extracellular vesicles, and exosomes, altogether known as secretome [10]. As the part of
composition of secretome, growth factors play a significant role in heart repair by promoting cell
proliferation, cytoprotection, and migration. The commonly secreted factors include
angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), basic fibroblast growth factor (bFGF), plateletderived growth factor (PDGF), vascular endothelial growth factor (VEGF), hepatocyte growth
factor (HGF), tumor necrosis factor alpha (TNF-a), collagens, insulin-like growth factor 1 (IGF1), interleukin-1 (IL-1), matrix metalloproteinases (MMPs), transforming growth factor beta
(TGF-b), tissue inhibitor of metalloproteinases (TIMPs), bone morphogenetic protein 4 (BMP4), interleukin-6 (IL-6), interleukin-7 (IL-7), neurotrophin-3 (NT-3), nerve growth factor (NGF),
glial cell line-derive neurotrophic factor (GDNF), and brain-derived neurotrophic factor (BDNF).
Among these factors, Ang-1, bFGF, IGF-1, IL-1, PDGF, VEGF, HGF, and TNF-a have been
shown to be useful to angiogenesis in the heart [10]. Except for angiogenesis, bFGF, HGF, IGF-1,
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IL-1, and VEGF also have been stated they have specific function in cardioprotection [10].
Moreover, several secreted factors can inhibit fibrosis, such as collagens, MMPs, TGF-b, and
TIMPs [10].
1.4 Delivery system for cell secretome
In order to deliver secretome to the damaged tissues, several approaches have been
investigated, such as transplantation of artificial cardiac patch encapsulated secreted factors from
stem cells, injectable and biocompatible hydrogels as carriers of secretome, injectable nanofibers
bonded with secretome, and biomimetic nanoparticles [11–15]. Huang et al. have developed
therapeutic cardiac patch to deliver the secreted factors of cardiac stromal cells to rat/porcine
heart after MI, and they found that the cardiac recovery was supported by reducing scarring and
improving angiomyogenesis [11]. An injectable hydrogel has been developed by Waters et al to
deliver secretome secreted by human adipose-derived stem cells to the peri-infarct myocardium,
leading to decreased scar area and increased cardiac function [12]. Webber et al. have designed a
factor-loaded injectable nanofiber network and injected into mouse heart after MI, and the
preservation of haemodynamic function was found by them [13]. Yasin et al have fabricated
nanoparticles loaded with VEGF to a murine myocardial infarction model, followed by
reductions infarct size and angiogenesis [16].
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Chapter 2 Modulation of Cardiac Fibroblast Secretome in Response to Different
Environmental Cues
2.1 Introduction
Compared to the disadvantages of stem cells, which are the unlimited cell types
differentiated from stem cells, the sophisticated extraction procedure, and high cost, the
advantage of cardiac fibroblasts (CFs) is prominent. CFs has been defined as the main effector to
prevent heart rupture by secreting factors in the infarcted heart [17]. Moreover, the large number
of CFs is easier to obtain compared to stem cells. Furthermore, the largest cell numbers in the
heart are cardiac fibroblasts, which has been shown to be conductive to mechanical, structural,
and biochemical properties of the heart [18]. Compared to other stem cells, CFs are the host cells
obtained the natural advantages. CFs also have been stated to be able to secrete a large number of
growth factors used in treatments for MI, such as VEGF, PDGF, bFGF, TNF-a, and IL-1b [19].
Furthermore, the secreted factors from CFs can protect cardiomyocytes from hypoxic condition,
induced hypertrophy, and ischemia injury [20].
2.2 Materials and methods
2.2.1 Materials
Acrylamide and N,N′-methylenebisacrylamide were purchased from Sigma-Aldrich.
N,N,N′,N′-Tetramethylethylenediamine (TEMED) and ammonium persulfate (APS) were
purchased from Bio-rad. Isopropanol was purchased form Fisher Scientific. Collagen type I was
obtained from Corning. Hydrophobic glass slides were purchased from Bio-rad. TRI Reagent
was purchased from Sigma. Acid phenol:CHCl3 was purchased from Ambion. Nuclease-free
water and SYBR Green were purchased from Thermo Scientific. High-capacity cDNA reverse
transcription kit was purchased from Thermo Fisher Scientific.
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2.2.2 RCF culture
Rat cardiac fibroblasts (RCFs) were cultured and seeded in a T75 flask with 10 mL
culture medium consisting of Dulbecco’s modified Eagle medium (DMEM), 12% fetal bovine
serum (FBS), and 1% penicillin/streptomycin under normal culture conditions (21% O2, 5%
CO2, 37°C). The culture medium was changed every two days and RCFs were passaged when
90% confluency was reached.
After 90% confluency was reached, RCFs were digested using 0.25% trypsin/EDTA for 5
mins at 37℃ and centrifuged at 1600 rpm for 7 min. Collected cells were seeded in 100-mm
dishes supplemented with culture medium consisting of DMEM, 12% FBS, and 1% penicillin.
The cells were maintained under normal culture conditions (21% O2, 5% CO2, 37°C) overnight.
The medium was then replaced with serum-free medium. One dish was incubated under hypoxic
condition (1% O2, 5% CO2, 37°C) for 24 hours. One dish was incubated under 5% O2 and 5%
CO2 at 37°C for 24 hours. One dish was incubated under normal culture condition (21% O2, 5%
CO2, 37°C) for 24 hours. After incubation, the media was aspirated, and the cells were lysed
using 1 mL of TRI reagent and then transferred into a 1.7 mL centrifuge tube to store at -80℃
for further experiments.
2.2.3 PAM gel fabrication and characterization
Acrylamide, bis-acrylamide, and APS were dissolved in deionized (DI) water to form
solutions with concentration of 40% w/v, 2% w/v, and 10% w/v, respectively. Polyacrylamide
(PAM) gel solution was prepared by mixing 40% w/v acrylamide solution, 2% w/v bisacrylamide solution, and DI water at 4 different ratios [21]. The ratio of these reagents and the
abbreviation of the corresponding gel were specified in Table 1. 5mL of polyacrylamide gel
solution was placed into a 50-mL tube. 25 μL of 10% w/v APS and 2.5 μL of TEMED were
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added into the same tube to achieve final concentration of 0.05% and 0.5%, respectively. The
solution was gently mixed by pipetting up and down 10 – 15 times. The gel solution was pipetted
onto the 0.75 mm space which was hold by two hydrophobic glass slides. 500 μL of isopropanol
was pipetted above the gel solution to remove bubbles. After 1 hour, the PAM gel was peeled off
carefully. To obtain a desired shape which was similar to the plate well of a 6-well plate, the cap
of a 50-mL tube was used to cut PAM gels to circles. One PAM gel was placed in each well by
forceps.
To determine PAM gels stiffness, the storage modulus was measured by rheometer. The
Young’s modulus, E was related to storage modulus by using the equation: 𝐸 = 𝐺 ! 2(1 + 𝑣),
where 𝑣, the Poisson ratio was approximated to 0.5 for PAM gel [22].
2.2.4 Collagen coating of PAM gels
Before coating, the 6-well plate was placed under an UV lamp for 1 hour while all PAM
gels were soaked in 1x phosphate buffered saline (PBS) to keep hydrated. 0.2 mg/mL collagen
solution was prepared by diluting the 3.78 mg/mL collagen type I solution in PBS. 500 μL of
diluted collagen solution was pipetted into each well to completely cover the gel surface. The
plate was covered by parafilm and placed at 4℃ overnight to allow collagen coating. After
aspirating collagen solution and rinsing with PBS to remove excess collagen solution, the plate
was placed in a biosafety cabinet under UV to sterilize for 1 hour.
2.2.5 Immunocytochemical staining
RCFs were cultured and seeded on PAM gels in 6-well plate with 2 mL culture medium
consisting of DMEM without serum at a hypoxia incubator (1% O2, 5%CO2, 37°C) overnight.
RCFs were fixed with 500 μL of 4% paraformaldehyde (PFA) solution. After fixation for 50
mins, blocking buffer was added to each well and incubated for 1 hour. Then, the fixed cells
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were incubated with mouse anti-alpha smooth actin-alpha (α-SMA, Abcam) at 4 C overnight.
Goat anti-mouse Alexa Fluor 647 (Invitrogen) was used as a secondary antibody to stain the cells
at room temperature for 1 hour. Nuclei and cytoplasm were stained with DAPI (Sigma) and Factin (Invitrogen), respectively. Fluorescent images were taken using a confocal microscope
(Olympus FV1200).
2.2.6 RCF secretome collection
After 90% confluency was reached, RCFs were digested using 0.25% trypsin/EDTA for 5
mins at 37℃. Collected cells were seeded onto the PAM gels supplemented with culture medium
consisting of DMEM, 12% FBS, and 1% penicillin. The cells were left to settle under normal
culture conditions (21% O2, 5% CO2, 37°C) overnight. The medium was then replaced with
serum-free medium, and the plate was incubated under hypoxic condition (1% O2, 5% CO2,
37 °C) for 24 hours. The medium of each PAM gel was collected, filtered by 0.22 μm filter, and
stored at –80°C for further experiments. The secretomes collected on 4 PAM gels with different
stiffness were named as PAM1, PAM2, PAM3, PAM4, respectively. The remaining cells were
collected for mRNA collection.
2.2.7 mRNA collection and concentration measurement
Cells from RCF secretome collection were lysed using 1 mL of TRI reagent and then
transferred into a 1.7 mL centrifuge tube to incubate at room temperature for 5 mins. 150 μL
phenol/CHCl3 was added to mixture until it became cloudy. The tube was vortexed for 20
seconds and then incubated at room temperature for 10 mins, followed by centrifugation at
12,000 g, 4℃ for 15 mins. After centrifugation, the upper transparent RNA-rich layer was
collected in a new 1.7 mL centrifuge tube, following by adding 150 μL isopropanol. The tube
was vortexed for 20 seconds and then incubated at room temperature for 15 mins. The tube was
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centrifuged at 12,000 g, 4°C for 10 mins. After centrifugation, the supernatant was removed,
followed by adding 150 μL of 75% ethanol (in DEPC water). The tube was vortexed for 20
seconds and centrifuged at 12,000 g, 4°C for 5 mins. After centrifugation, the supernatant was
removed. The open capped tube was placed in the biosafety cabinet for 20 mins to air-dry. 22 μL
nuclease free water was added to dissolve the remaining RNA. RNA concentration was
measured by NanoDrop (ND-1000 Spectrophotometer) for cDNA synthesis.
2.2.8 cDNA synthesis
Complementary DNA (cDNA) was synthesized at 1000 ng/reaction using a high capacity
cDNA reverse transcription kit (Thermo Fisher) by Mastercycler (Eppendorf). The synthesized
cDNA was stored at – 20°C for Real-time RT-PCR.
2.2.9 Real-time RT-PCR
As described at cDNA Synthesis, cDNA was obtained. SYBR green (Invitrogen) and
selected primer pairs (Table 2) were mixed to perform real-time RT-PCR. β-actin was served as
a housekeeping gene. Fold of increase was calculated using ΔΔCt method.
2.2.10 Sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE)
Protein concentration was measured using Bradford protein assay.
Mini-protean TGX stain-free precast gel (Bio-rad) was used to load proteins. 20 ug protein was
loaded in each lane. The running buffer for SDS-PAGE was 25 mM Tris, 190 mM glycine and
0.1% SDS. The voltage was kept at 30 V for 15 min and 80 V for 1 hour. The images of the gel
were obtained by Chemi-Doc XRS+ system (Bio-rad)
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2.2.11 Enzyme-linked immunosorbent assay (ELISA)
100 µL diluted capture antibody was added to each well of a 96-well plate, followed by
sealing with parafilm and incubating overnight at room temperature. The remaining liquid was
aspirated, following by washing with wash buffer (0.05% Tween-20 in PBS) for 4 times. After
that, 300 µL block buffer (1% bovine serum albumin in PBS) was added to each well and
incubated for 1 hour at room temperature. Then, liquids were aspirated, and the plate was washed
with wash buffer for 4 times. Serial diluted standard protein and release media were added to the
plate with replicate number of 3, followed by incubating at 4℃ overnight. Then, the remaining
liquid was aspirated, followed by washing with wash buffer for 4 times. Diluted detection
antibody was added to each well and incubated for 2 hours at room temperature. After that, the
liquids were aspirated and followed by washing with wash buffer for 4 times. Diluted AvidinHRP conjugate was added to each well and incubated for 30 min at room temperature. Then, the
liquids were aspirated and followed by washing with wash buffer for 4 times. ABTS liquid
substrate solution was added to each well and incubated at room temperature in the dark. The
color development was monitored by a plate reader at 405 nm with wavelength correction at 650
nm.
2.2.12 HUVEC culture
Human umbilical vein endothelial cells (HUVECs) were cultured and seeded in a T75
flask supplemented with 10 mL culture medium consisting of EBM and EGM-2 SingleQuots
(Lonza) under normal culture conditions (21% O2, 5% CO2, 37°C). The culture medium was
changed every two days and HUVECs were passaged when 90% confluence was reached.
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2.2.13 HUVEC survival (MTT assay)
As previously described at RCF secretome collection, the medium of each PAM gel was
collected. The medium of PAM2 and EBM without serum were blended at a ratio of 1:1 at a T25
flask, following by being incubated under hypoxic condition (1% O2, 5% CO2, 37°C) for over 24
hours to allow gas balance. The medium of PAM4 and EBM without serum were blended at a
ratio of 1:1 at a T25 flask, following by being incubated under hypoxic condition (1% O2, 5%
CO2, 37°C) for over 24 hours. All media used in this experiment was stored at hypoxic incubator
(1% O2, 5% CO2, 37°C) for future experiments. Also, EBM without serum was placed to a T25
flask and incubated under hypoxic condition (1% O2, 5%CO2, 37 °C) for over 24 hours, named
as Control medium stored at hypoxic incubator (1% O2, 5% CO2, 37°C) for further experiments.
HUVECs were cultured and seeded in two 96-well plates (concentration of 30,000
cells/mL) with replicate number of 10 for each group supplemented with 200 µL culture
medium. The cells were maintained under normal culture conditions (21% O2, 5% CO2, 37°C)
overnight. Without changing culture medium, two plates were transferred to hypoxic incubator
(1% O2, 5% CO2, 37°C) and incubated. At day 0 and day 4, cell viability was measured for
control group, PAM2 group (secretome collected on PAM2 gel blended with EBM) and PAM4
group (secretome collected on PAM4 gel blended with EBM) using MTT assay. Briefly, 20 µL 5
mg/mL MTT solution was added to each well to incubate for 4 hours. After that, the medium
was removed carefully and 200 µL DMSO was added to each well, following by shaking for 10
mins to dissolve all solids at bottom and reading the absorbance at 560 nm by a plate reader, and
substracting background at 670 nm.
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2.2.14 HUVEC migration
HUVECs were cultured and seeded in a 24-well plate (concentration of 175,000
cells/mL) with replicate number of 4 for each group supplemented with 800 μL culture medium.
The cells were left to settle under normal culture conditions (21% O2, 5% CO2, 37°C). After
~90% confluency was reached, the cell monolayer was scratched using a pipette tip, and the cells
were treated with EBM medium (control group) and secretome collected on PAM2 gel blended
with EBM (PAM2 group). At 0, 15, 24, and 40 hours, cell migration was quantified by taking
images with an optical microscope (Olympus IX70).
2.2.15 HUVEC tube formation
Three-dimensional collagen gel solution was prepared by mixing 3.78 mg/mL collagen
type I solution, 5x DMEM, 1x DMEM, and FBS and adjusting pH to 7.3 by adding 1 M NaOH,
followed by pipetting up and down 10 times. 500 µL solution was added to each well of a 48well plate with replicate number of 2 for each group. After 1-hour incubation, the remaining
liquid was aspirated, following by washing with PBS for 2 times.
HUVECs were seeded in collagen gels (concentration of 50,000 cells/mL) supplemented
with 400 µL culture medium. The cells were left to settle under normal culture conditions (21%
O2, 5% CO2, 37°C) for 24 hours. The cells were treated with EBM medium (control group) and
secretome collected on PAM2 gel blended with EBM (PAM2 group). After 24-hour incubation,
the medium was aspirated, following by washing with PBS. HUVECs were fixed using 4% PFA
for 50 min, followed by washing with PBS for 4 times. After that, cells were blocked using
blocking buffer for 40 min, followed by washing with PBS. The diluted F-actin and DAPI were
used to stain cells for 1 hour, followed by washing with PBS for 5 times. Fluorescent images
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were taken for each collagen gel using Olympus FV1200 confocal microscope. The tube density
was quantified from large lumens.
2.2.16 Cardiomyocyte culture
Rat neonatal cardiomyocytes were purchased from Lonza and cultured per
manufacturer’s instruction. Briefly, the cells were seeded in nitrocellulose-coated plates with rat
cardiomyocyte growth media (rCGM, Lonza). Bromodeoxyuridine was added to the culture
media to suppress fibroblast formation.
2.2.17 Cardiomyocyte survival (MTT assay)
Cardiomyocytes were seeded in two 96-well plates (concentration of 10,000 cells/mL)
with replicate number of 5 for each group supplemented with 200 µL culture medium. At day 0
and day 2, cell viability was measured for control group, PAM2 group (secretome collected on
PAM2 gel blended with EBM) and PAM4 group (secretome collected on PAM4 gel blended
with EBM) using MTT assay. Briefly, 20 µL 5 mg/mL MTT solution was added to each well to
incubate for 4 hours. After that, the medium was removed carefully and 200 µL DMSO was
added to each well, following by shaking for 10 mins to dissolve all solids at bottom and reading
the absorbance at 560 nm by a plate reader, and substracting background at 670 nm.
2.2.18 Statistical analysis
All data were presented as mean ± standard deviation. One-way ANOVA was used to
analyze the significant difference between experimental groups. The significant difference was
defined as p < 0.05.
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2.3 Results and Discussion
2.3.1 Gene expression of RCF secretome in response to oxygen content
To investigate how the RCF secretome changed in response to environmental oxygen
content, the growth factor expressions were quantified at the mRNA level under 1% O2, 5% O2,
and 21% O2 culture conditions. RCF secretome under 1% O2 exhibited significantly higher
Vascular endothelial growth factor (VEGF) expression than 5% O2 (p<0.0001) and 21% O2
(p<0.0001) (Figure 1a). Besides VEGF, the 1% O2 group had significantly lower interleukin
(IL1β) expression (p<0.05) and transforming growth factor β (TGFβ) expression (p<0.001) than
21% O2, whereas 1% O2 and 5% O2 had similar expressions (p>0.05) (Figure 1b, 1c).
VEGF is one of the most effective proangiogenic factors [23]. It also plays a crucial role in
promoting the formation of new blood vessels in the heart with myocardial infarction or other
ischemic heart diseases [16]. Thus, the significantly higher VEGF expression was the advantage
of 1% O2 group compared to other groups. Moreover, suppression of IL1β has been proven to be
a treatment in myocardial infarction [24]. It has been shown that the expression of genes which are
essential to the regulation of calcium homeostasis are reduced by IL1β [25]. The expression of
nitric oxide synthase in cardiac myocytes is promoted by IL1β [26]. In addition, TGFβ has been
proven to induce myocardial infarction and activate fibrosis in the infarcted heart [27]. Therefore,
the lower expression of IL1β and TGFβ was another advantage of 1% O2 group compared to
other groups. The above results reveal that the lower environmental oxygen content significantly
optimized RCF secretome. Hypoxic culture condition (1% O2, 5% CO2, 37°C) was chosen for
further experiments.
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2.3.2 PAM Gel Fabrication and Characterization
PAM gels were fabricated with four different concentrations of acrylamide and
crosslinker bis-acrylamide and cut to circles (Figure 2a). To determine PAM gels stiffness, the
storage modulus was measured by using rheometer (Table 3). The Young’s modulus, E was
related to storage modulus by using the equation: 𝐸 = 𝐺 ! 2(1 + 𝑣), where 𝑣, the Passion ratio
was approximated to 0.5 for PAM gels [22]. For PAM1 which contained 5% acrylamide and 0.1%
crosslinker bis-acrylamide, its storage modulus was 0.43 ± 0.02 kPa and Young’s modulus was
1.29 ± 0.05 kPa. For PAM2 which contained 8% acrylamide and 0.1% crosslinker bisacrylamide, its storage modulus was 2.04 ± 0.10 kPa and Young’s modulus was 6.11 ± 0.31 kPa.
For PAM3 which contained 8% acrylamide and 0.25% crosslinker bis-acrylamide, its storage
modulus was 4.82 ± 0.09 kPa and Young’s modulus was 14.46 ± 0.27 kPa. For PAM4 which
contained 12% acrylamide and 0.25% crosslinker bis-acrylamide, its storage modulus was 10.83
± 0.10 kPa and Young’s modulus was 32.50 ± 0.31 kPa (Figure 2b). These results confirmed that
the stiffness of PAM gel was controllable by adjusting the concentration of acrylamide or
crosslinker (bisacrylamide) concentration. We found that higher acrylamide or crosslinker
(bisacrylamide) concentration resulted in stiffer PAM gel.
To determine RCF morphology and the tendency to differentiate into myofibroblasts,
immunocytochemical staining of SMA was performed, and the fluorescent images were taken
for RCF on PAM1 to 4 and normal culture plate (Figure 3). α-SMA is regarded as a marker for
myofibroblasts [28]. With the increase of stiffness, the α-SMA expression increased and the RCFs
were observed to differentiate into myofibroblasts. The above results demonstrate that the
stiffness of PAM gel could affect the α-SMA expression. Higher stiffness of PAM gel could lead
to more α-SMA expression. RCFs would differentiate into myofibroblasts on a stiffer substrate.
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Fibroblasts has been shown to proliferate, migrate, and regulate cardiac extracellular
matrix (ECM), leading to sustain cardiac homeostasis [29]. Myofibroblasts are differentiated from
fibroblasts, which are unusually present in the healthy myocardium, but normal in the infract
scar, leading to fibrogenesis [30]. The activeness of myofibroblasts in healthy area of the heart can
lead to fibrosis and adverse myocardial remodeling [31]. Myocardial remodeling (REM) is a
detrimental process of changing in the heart’s size and shape, being caused by myocardial
infarction [32]. High myofibroblast density in the remote myocardium results in increased
myocardial stiffness, leading to systolic and diastolic dysfunction and heart failure [29].
Moreover, compared to the proven myocyte hypertrophy caused by secretome activated
myofibroblasts, secretome of CFs has been performed to protect cardiomyocytes from induced
hypertrophy [20,33]. Therefore, the PAM gel with less α-SMA expression performed greater than
others.
2.3.3 Effects of PAM gels on RCF secretome under hypoxic condition
To investigate how the stiffness of PAM gels affects RCF secretome under hypoxic
condition, the total amounts of protein in RCF cultured on PAM1 to 4 were measured by running
SDS-PAGE (Figure 4). Compared to other three groups, the PAM2 groups expressed apparently
much greater amount of protein.
To determine how RCF paracrine effects were expressed on PAM gels under hypoxic
condition, the growth factor expressions were quantified at the RNA level. For basic fibroblast
growth factor (bFGF), the PAM2 group exhibited significantly higher than PAM3 group
(p<0.05) and PAM4 group (0.01) (Figure 5a). For platelet-derived growth factor (PDGF), the
PAM2 group also performed significantly higher than PAM3 group (p<0.01) and PAM4 group
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(p<0.0001) (Figure 5b). For VEGF, the PAM2 group also performed significantly higher than
PAM3 group (p<0.05) (Figure 5c).
bFGF has been shown to be a protective role in myocardial infarction and hypoxia
cardiomyocytes [34]. Also, bFGF can promote cardiac stem cell migration, reduce infarct size,
and enhance cardiac systolic function [35,36]. Moreover, it has been shown that PDGF is one of the
growth factors which can promote cell growth, differentiation, proliferation, and migration,
leading to stimulate angiogenesis [37]. The importance of VEGF in myocardial infarction has
been discussed before. Thus, the significantly higher expressions of PDGF, VEGF, and bFGF
were the advantage of PAM2 group compared to other three groups. The above results
demonstrate that PAM2 gel optimized RCF secretome under hypoxic condition.
To determine the concentration of bFGF of RCF secretome collected on PAM1 to 3
under hypoxia, ELISA was used to measure. The PAM2 gel significantly increased the
concentration of bFGF in RCF secretome compared to PAM1 (p<0.01) and PAM3 (p<0.01)
(Figure 6). These results demonstrate that PAM2 significantly enhanced the amount of bFGF in
RCF secretome under hypoxia.
Therefore, based on the above results, PAM2 group was chosen for further experiments.
2.3.4 Effects of RCF secretome on HUVEC survival, migration and tube formation under
hypoxic condition
Endothelial cells play a pivotal role in angiogenesis, which is a crucial process after
myocardial infarction. The survival, migration and fusion of endothelial cells is the prerequisite
for formation of new blood vessels [38].
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To investigate whether the PAM2 can increase HUVEC survival under hypoxic
condition, HUVECs were cultured using three different culture media. Control group was used
with serum-free medium; PAM2 group was used with serum-free medium and PAM2 medium at
ratio of 1:1; PAM4 group was used with serum-free medium and PAM4 medium at ratio of 1:1.
Although the cell viability of all three groups at day 4 decreased compared to day 0, the cell
number of PAM2 group was significantly higher than control group (p<0.0001) and PAM4
group (p<0.01) (Figure 7). Moreover, there was no significant difference between control group
and PAM4 group (p>0.05). The in vitro results reveal that the secretome collected on low
stiffness promoted HUVEC survival under hypoxic condition, but the secretome collected on
high stiffness did not have much greater effect than serum-free medium. Thus, PAM2 medium
was used for further experiment.
To determine whether the RCF secretome collected on PAM2 enhanced HUVEC
migration, the migration ratio of two groups (Control and PAM2) was statistically measured
based on images taken at 0, 15, 24, and 40 hours (Figure 8a). For control group, the migration
ratios at 15, 24, and 40 hours were lower than 20%. For PAM2 group, the migration ratios at 15,
24, and 40 hours were persistently increasing. At these three time spots, PAM2 group had
significantly greater migration ratios than control group (p<0.0001) (Figure 8b).
To investigate whether the RCF secretome collected on PAM2 promoted HUVEC tube
formation, the normalized tube density of two groups was statistically measured based on
fluorescent images taken after 24-hour incubation (Figure 9a). For the number of cells, PAM2
group performed apparently much greater than control group. Besides the number of cells,
PAM2 group had significantly greater tube density than control group (p<0.001) (Figure 9b).
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The above results reveal that the RCF secretome collected on PAM2 played an essential role on
HUVEC survival, migration, and tube formation.
2.3.5 Effect of RCF secretome on cardiomyocytes survival under hypoxic condition
To investigate whether the PAM2 can increase cardiomyocytes survival under hypoxic
condition, cardiomyocytes were cultured using three different culture media. Control group was
used with serum-free medium; PAM2 group was used with serum-free medium and PAM2
medium at ratio of 1:1; PAM4 group was used with serum-free medium and PAM4 medium at
ratio of 1:1. Although the cell viability of all three groups at day 2 decreased compared to day 0,
the cell number of PAM2 group were significantly higher than control group (p<0.01) and
PAM4 group (p<0.001) (Figure 10). Moreover, there was no significant difference between
control group and PAM4 group (p>0.05). The in vitro results reveal that the secretome collected
on low stiffness protected cardiomyocytes under hypoxic condition, but the secretome collected
on high stiffness did not have greater effect than serum-free medium.
2.4 Conclusion
In this work, RCF secretome was modulated in response to different environmental
oxygen contents and stiffness. Under hypoxic culture condition (1% O2, 5% CO2, 37°C), the
RCF secretome collected on PAM2 gel exhibited greater secretion of growth factors cytokines at
both RNA and protein level. Higher cell survival ratio, migration ratio, and tube formation ratio
confirmed the useful treatment of optimized RCF secretome. This modulation of cardiac
fibroblast secretome may promote heart repair after myocardial infarction.
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Chapter 3 Targeted Delivery of Platelet Membrane Coated PLGA Nanoparticles with
Sustained Cardiac Fibroblast Secretome Release
3.1 Intro
Among the current delivery methods, such as injectable hydrogel and transplantation of
patch, they are limited by indirect delivery with a surgery to open chest, leading to high risk to
break myocardium [39]. In addition, nanoparticle delivery system is a minimally-invasive method
by intravenous injection, and its size is small enough to circulate in the blood stream [40]. To
overcome the limitations of nanoparticle, such as short retention and potential immune rejection,
a cell-membrane coated nanoparticle delivery system has been designed [41]. Among various cell
membranes, platelet membrane coating has advantage of avoiding immune rejection, capability
of ligand binding and selectively binding to injured endothelium by nature. The objective of this
work is to coat platelet membrane with nanoparticles to targeted bind to the injured endothelium
[42]

.

3.2 Materials and methods
3.2.1 Materials
Poly (lactide-co-glycolic acid) (PLGA, LACTEL) with a LA/GA ratio of 50/50 was
purchased from Lactel Absorbable Polymers.
3.2.2 Secretome collection
As described at RCF secretome collection, the medium of PAM2 was collected, filtered
by 0.22 μm filter, and freeze-dried. The powder was dissolved in 2 mL DI water, and
concentrated using vivaspin 500 concentrator (MWCO=3kDa) to obtain a desalted secretome
solution for nanoparticle fabrication.
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3.2.3 Nanoparticle fabrication and characterization
100 mg PLGA was weighed and dissolved in 2 mL dichloromethane (DCM). 200 µL
secretome solution was emulsified with PLGA solution using an ultrasonicator for 1 min to
obtain a homogeneous and opaque solution. The solution was quickly transferred into a beaker
with 8 mL of 1% w/v polyvinyl alcohol (PVA) water solution, following by 1-minute
ultrasonication. After that, the beaker was placed on a magnetic stirring plate with a moderate
stirring speed at room temperature overnight to evaporate solvent. The remaining solution was
transferred into a 50-mL tube, following by adding DI water to 35 mL and centrifuging at speed
of 12,000 rpm for 15 mins. After centrifugation, the supernatant was removed carefully. The
centrifugation/resuspension process was repeated for 4 times to remove PVA. After that, the
washed nanoparticles were freeze-dried, collected, and stored at -80℃ for further experiments.
The size distribution of nanoparticles was measured by dynamic light scattering at room
temperature. The samples were prepared by diluting nanoparticles with DI water and filtering
with a 0.45 µm membrane filter.
3.2.4 Growth factor release characterization
75 mg of fabricated nanoparticles was weighed and suspended in 5 mL PBS with 1%
penicillin to achieve a final concentration of 15 mg/mL. The suspension was evenly separated
into twelve 1.7-mL centrifuge tube and incubated in a 37℃ water bath for release. At day 1, 2, 3,
5, 7, 10, and 14, the release media were collected and stored at -80℃ for further experiments.
The concentration of growth factor was measured by ELISA [43,44]. 100 µL diluted
capture antibody was added to each well of a 96-well plate, followed by sealing with parafilm
and incubating overnight at room temperature. The remaining liquid was aspirated, followed by
washing with wash buffer (0.05% Tween-20 in PBS) for 4 times. After that, 300 µL block buffer
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(1% Bovine Serum Albumin in PBS) was added to each well and incubated for 1 hour at room
temperature. Then, liquids were aspirated, and the plate was washed with wash buffer for 4
times. Serial diluted standard and release media were added to the plate with replicate number of
3, followed by incubating at 4℃ overnight. Then, the remaining liquid was aspirated, followed
by washing with wash buffer for 4 times. Diluted detection antibody was added to each well and
incubated for 2 hours at room temperature. After that, the liquids were aspirated and followed by
washing with wash buffer for 4 times. Diluted Avidin-HRP conjugate was added to each well
and incubated for 30 mins at room temperature. Then, the liquids were aspirated and followed by
washing with wash buffer for 4 times. ABTS liquid substrate solution was added to each well
and incubated at room temperature in the dark. The color development was monitored by a plate
reader at 405 nm with wavelength correction set at 650 nm.
3.2.5 Platelet membrane coating and characterization
The platelet rich plasma was extracted from bovine blood. Three freeze-thaw processes
were conducted on the platelets in a 1.7-mL centrifuge tube to break the cell membrane. After
the final thaw process, the tube was centrifuged at 4,500 g for 5 min at room temperature. Then,
the pelleted platelet membrane was washed with PBS containing protease inhibitor for 3 times.
After sonication for 5 min, 2 mg freeze-dried nanoparticles were added into 2 mL platelet
membrane solution, following by sonicating for 5 mins. The platelet membrane coated (PLMcoated) nanoparticles were stored at 4℃ for further experiments.
The size distribution of platelet membrane coated nanoparticles was measured by
dynamic light scattering at room temperature. The samples were prepared by diluting
nanoparticles with DI water and filtering with a 0.45 µm membrane filter.
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3.2.6 Cell uptake
As described at Platelet membrane coating and characterization, PLM-coated
nanoparticles were obtained. Ischemia-targeting peptide CSTSMLKAC (CST) in NaH2PO4
buffer was mixed with PLM-coated nanoparticles, following by adding suberic acid bis(Nhydroxysuccinimide ester) dissolved in DMSO and stirring at room temperature for 2 hours.
After adding glycine and dialyzing against DI water overnight, CST conjugation was finished.
Glass slides were placed in a 24-well plate, coated with collagen, and incubated for 1
hour at room temperature. After the remaining liquids were aspirated, the plate was placed in a
biosafety cabinet under UV to sterilize for 1 hour. HUVECs and RCFs were cultured and seeded
in the glass slides (concentration of 50000 cells/mL) with replicate number of 2 for each kind of
cells supplemented with 800 μL culture medium. The cells were left to settle under normal
culture conditions (21% O2, 5% CO2, 37°C). After 24-hour incubation, the medium was replaced
with 1 mg/mL diluted, conjugated PLM-coated nanoparticles with normal medium. After 24hour incubation, the medium was aspirated, following by washing with PBS. HUVECs and
RCFs were fixed using 4% PFA for 50 mins, following by washing with PBS for 4 times. After
that, cells were blocked using blocking buffer for 40 mins, following by washing with PBS. The
diluted F-actin and DAPI were used to stain cells for 1 hour, following by washing with PBS for
5 times. Fluorescent images were taken for each glass slide using Olympus FV1200 confocal
microscope. The ratios of cell uptake were quantified by measuring the number of cells which
have nanoparticles inside divided by total number of cells.
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3.2.6 Statistical analysis
All data were presented as mean ± standard deviation. One-way ANOVA was used to
analyze the significant difference between experimental groups. The significant difference was
defined as p < 0.05.
3.3 Results and Discussion
3.3.1 Fabrication and characterization of PLGA nanoparticles
The PLGA nanoparticles were fabricated by the method of double emulsion to form coreshell structure with PLGA as shell and RCF secretome as core. The size of uncoated PLGA
nanoparticles was 218.33 nm with a PDI of 0.17, while the size of PLM-coated PLGA
nanoparticles was 239.80 with a PDI of 0.04 (Figure 11a). The results demonstrate that the size
of nanoparticles increased after coating with platelet membrane (Table 3). The size of PLGA
nanoparticles did not change significantly within 30-day incubation in PBS at 37ºC (Figure 11b).
The above results reveal that the PLGA nanoparticles were stable in physiological environment.
3.3.2 Growth factor release kinetics
To determine how different growth factors released from the nanoparticles, the
concentrations of PDGF, VEGF, and bFGF in release media were measured and calculated by
performing ELISA (Figure 12). The above results demonstrate that the growth factors were
sustainedly released by nanoparticles in 37°C over 14 days.
Herein, among PDGF, VEGF, and bFGF, they all play essential roles in the treatment of
myocardial infarction. The sustained release delivery system is useful to avoid a consequence
that the loaded secretome are metabolized and eliminated from the body too fast to achieve the
desired therapeutic effect [45].
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3.3.3 Cell uptake for platelet membrane coated nanoparticles
To investigate how the platelet membrane affected HUVEC and RCF uptake
nanoparticle, the ratio of cell uptake was quantified by counting the number of cells endocytosed
nanoparticles. For both of HUVEC and RCF, the ratios of cell uptake were lower than 15%
(Figure 13).
3.4 Conclusion
In this work, a RCF secretome release system was designed and fabricated. The RCF
secretome nanoparticles exhibited sustainedly release RCF secretome and stability in
physiological environment. This delivery system may have the potential treatment for the heart
repair following myocardial infarction.
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Chapter 4 Future Work
The PLM-coated PLGA nanoparticles can sustainedly release the loaded RCF secretome
which is modulated based on hypoxic culture condition and environmental stiffness. However,
we still do not know whether the amount of secretome loaded is enough to promote heart repair
following myocardial infarction. The effect of secretome loaded nanoparticles should be tested
by further and deeper experiments in vitro and in vivo. Thus, the therapeutic effect of this
nanoparticles can be exhibited.
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Table 1. Concentration of acrylamide and bis-acrylamide of PAM gels.

Acrylamide
Bis-acrylamide
Polyacrylamide

Acrylamide

Bis-

from

40%

hydrogel

%

acrylamide %

stock solution

DI water
from 2% stock
(mL)
solution (mL)

(mL)
PAM1

5

0.1

0.625

0.25

4.125

PAM2

8

0.1

1

0.25

3.75

PAM3

8

0.25

1

0.625

3.375

PAM4

12

0.25

1.5

0.625

2.875

Table 2. Primer sequences used in real-time RT-PCR.
Forward primer

Reverse primer

VEGF

TATCTTCAAGCCGTCCTGTG

GATCCGCATGATCTGCATAG

PDGFBB

AAATCGTGGAAGACATGAAC

TTCACAAGCACAATGCAC

TGFβ

ATATAGCAACAATTCCTGGC

CGTGGAGTACATTATCTTTGC

bFGF

AACTACAGCTCCAAGCAG

GTAACACACTTAGAACCAG

IL1β

CACCTCTCAAGCAGAGCACAG

GGGTTCCATGGTGAAGTCAAC
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Table 3. PAM gel stiffness measured by rheology.
Polyacrylamide

Young’s Modulus E ± SD
Storage Modulus G’ ± SD (kPa)

hydrogel

(kPa)

PAM1

0.43 ± 0.02

1.29 ± 0.05

PAM2

2.04 ± 0.10

6.11 ± 0.31

PAM3

4.82 ± 0.09

14.46 ± 0.27

PAM4

10.83 ± 0.10

32.50 ± 0.31

Table 4. Size and PDI of uncoated and PLM-coated nanoparticles.
Z-average (nm)

PDI

Uncoated nanoparticle

218.33

0.17

PLM-coated nanoparticle

239.80

0.04
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Figure 1. Gene expression of VEGF, IL1β, and TGFβ in RCF under 1% O2, 5% O2, and 21% O2
culture conditions. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001

Figure 2. Fabricated PAM gel and stiffness of PAM gels as measured by rheometer.
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Figure 3. Immunocytochemical staining of F-actin (green) and α-SMA (red) of RCF cultured on
PAM1 to 4 and culture plate. Nuclei were stained with DAPI (blue).

Figure 4. Protein expression of RCF cultured on PAM1 to 4 gels.
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Figure 5. Gene expression of RCF cultured on PAM1 to 4. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001

bFGF concentration (pg/mL)

bFGF

**

150

PAM1

**

PAM2

100

PAM3

50

0
PAM1

PAM2

PAM3

Figure 6. Concentration of bFGF of RCF secretome collected on PAM1 to 3. *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001
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Cell viability (%)

150

Control
PAM2

100

PAM4

****
**
50

0
Day0

Day4

Figure 7. In vitro HUVEC survival under hypoxic condition. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001

Figure 8. In vitro HUVEC migration under hypoxic condition. scale bar = 200 µm, *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001

32

Figure 9. In vitro HUVEC tube formation under hypoxic condition with quantification. Nuclei and
cytoplasm were stained with DAPI (blue) and F-actin (green). *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001

Cell viability (%)

150

Control
PAM2

100

PAM4

*
**

50

0
Day0

Day2

Figure 10. In vitro cardiomyocytes survival under hypoxic condition. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001
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Figure 11. DLS of uncoated and PLM-coated nanoparticles and stability of uncoated
nanoparticles.

Figure 12. Growth factor release kinetics. The PDGF, bFGF, and VEGF release of the
uncoated nanoparticles was tested for 14 days under 37℃.
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Figure 13. Cell uptake of PLM-coated nanoparticles with quantification.
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